3 Pharma Excipients and Food Ingredients Maker, Respiratory Medicines Company and Fluorospecialty Chemicals Group Stocks With a Strong Future Roadmap: Sudeep Pharma, Cipla and SRF
- October 30, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Sudeep Pharma, Cipla and SRF: ROE of 11.3% to 19.6% and FY22 to FY26 revenue CAGR of 6.1% to 17.6%. Prices as of 29 Oct 2026.
Quick Answer
The three excipient, respiratory drug and fluorine stocks to watch are Sudeep Pharma, Cipla and SRF. Their return on equity ranges from 11.3% to 19.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.1% to 17.6%. Sudeep Pharma leads on both return on equity at 19.6% and revenue growth at 17.6% a year. Prices are based on the 29 October 2026 close, and this article is educational, not investment advice.
Excipient, respiratory drug and fluorine stocks offer a focused view of a sector where demand keeps widening. Sudeep Pharma, Cipla and SRF cover a pharma excipients and food ingredients maker, a respiratory medicines company and a fluorospecialty chemicals group.
This list covers three excipient, respiratory drug and fluorine stocks with complete current figures: Sudeep Pharma, Cipla and SRF. Every figure comes from the latest reported financials and the 29 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Excipient, Respiratory Drug and Fluorine Stocks?
Excipient, respiratory drug and fluorine stocks are listed companies that make excipients and nutritional additives for drug and food makers, sell respiratory and chronic care medicines and produce refrigerant gases, fluorospecialty chemicals and packaging films. Their earnings depend on export orders, approvals and product mix.
Excipient, Respiratory Drug and Fluorine Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Sudeep Pharma | 1,130.1 | 11,352 | 61.8 | 35.1 | 19.6 | 0.17 |
| Cipla | 1,358 | 107,528 | 32.0 | 36.0 | 11.3 | 0.02 |
| SRF | 2,358.6 | 69,274 | 30.4 | 33.9 | 14.9 | 0.35 |
On valuation, Cipla and SRF trade at a P/E below the industry P/E, while Sudeep Pharma trades above it, which reflects the growth the market already expects. Readers comparing excipient, respiratory drug and fluorine stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Excipient, Respiratory Drug and Fluorine Stocks Have a Strong Roadmap in India?
Excipient, respiratory drug and fluorine stocks have a strong roadmap in India because global demand for nutrition and fortification products, steady medicine needs and wider use of specialty chemicals keep widening the market for these companies.
- Nutrition demand. Fortified foods need specialty ingredients.
- Respiratory care. Chronic conditions bring repeat prescriptions.
- Specialty chemistry. Fluorochemicals serve many end uses.
Why Sudeep Pharma Features Among These Excipient, Respiratory Drug and Fluorine Stocks
Among the excipient, respiratory drug and fluorine stocks on this list, Sudeep Pharma makes pharmaceutical excipients, food ingredients and nutritional additives such as minerals and fortification products for domestic and global customers.
Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%.
In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P/E of 61.8, above the industry P/E of 35.1.
Roadmap: Excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.
What to watch: Check capacity expansion progress and export revenue growth.
Why Cipla Features Among These Excipient, Respiratory Drug and Fluorine Stocks
Among the nutrition and pharma exporters shares on this list, Cipla is a Mumbai-based pharmaceutical company with strengths in respiratory medicines, anti-infectives and chronic therapies. It sells branded and generic products in India, South Africa, the United States and other markets.
In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%.
Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0.
Roadmap: The company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.
What to watch: Follow new product launches in the United States and the growth of key domestic brands.
Why SRF Features Among These Excipient, Respiratory Drug and Fluorine Stocks
Among the three companies on this list, SRF is a diversified chemicals and materials company with fluorospecialty chemicals, refrigerant gases, packaging films and technical textiles, with customers in India and overseas.
The company has a return on equity of 14.9%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 69,274 crore. The stock trades at a P/E of 30.4, below the industry P/E of 33.9.
Revenue rose from Rs 12,549 crore in FY22 to Rs 15,894 crore in FY26, a compound annual growth rate of 6.1%. Net profit grew from Rs 1,336 crore in FY24 to Rs 1,835 crore in FY26, which works out to a compound annual growth rate of 17.2%.
Roadmap: The company is expanding in specialty chemicals and refrigerant gases while its packaging films and technical textiles businesses add scale. A mix of segments spreads earnings.
What to watch: Track specialty chemicals growth, refrigerant gas demand and capacity additions.
Sudeep Pharma vs Cipla vs SRF on Key Financials
The table below sets the three excipient, respiratory drug and fluorine stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Sudeep Pharma | 350 | 671 | 17.6% | 174 | 26.0% |
| Cipla | 22,044 | 29,045 | 7.1% | 3,870 | 13.3% |
| SRF | 12,549 | 15,894 | 6.1% | 1,835 | 11.5% |
Sudeep Pharma posts the highest return on equity in this group at 19.6%. Cipla has the largest FY26 revenue at Rs 29,045 crore, and Sudeep Pharma shows the fastest revenue growth with a 17.6% compound annual rate. A useful habit with excipient, respiratory drug and fluorine stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Excipient, Respiratory Drug and Fluorine Stocks
Every theme carries risks that deserve a check before any decision. For these excipient, respiratory drug and fluorine stocks, the main points are:
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Raw material and energy costs. Input prices can move margins in chemicals.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter excipient, respiratory drug and fluorine stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Excipient, Respiratory Drug and Fluorine Stocks
Excipient, respiratory drug and fluorine stocks reward patient research into demand, execution and financial strength. Sudeep Pharma, Cipla and SRF each have a clear plan to grow. Based on the 29 October 2026 close, Sudeep Pharma trades at Rs 1,130.1, Cipla at Rs 1,358 and SRF at Rs 2,358.6.
Download the Univest iOS App or Univest Android App to track excipient, respiratory drug and fluorine stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are excipient, respiratory drug and fluorine stocks?
Ans. Excipient, respiratory drug and fluorine stocks are listed companies that make excipients and nutritional additives for drug and food makers, sell respiratory and chronic care medicines and produce refrigerant gases, fluorospecialty chemicals and packaging films. Their earnings depend on export orders, approvals and product mix. This list looks at three of them, Sudeep Pharma, Cipla and SRF, using reported FY22 to FY26 financials and the 29 October 2026 closing prices.
Which excipient, respiratory drug and fluorine stocks are covered in this list?
Ans. This list covers Sudeep Pharma, Cipla and SRF. Based on the 29 October 2026 close, Sudeep Pharma traded at Rs 1,130.1, Cipla at Rs 1,358 and SRF at Rs 2,358.6. Their return on equity ranges from 11.3% to 19.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.1% to 17.6%.
Why do excipient, respiratory drug and fluorine stocks have a strong future roadmap in India?
Ans. Excipient, respiratory drug and fluorine stocks have a strong roadmap in India because global demand for nutrition and fortification products, steady medicine needs and wider use of specialty chemicals keep widening the market for these companies. The main drivers are as follows. Nutrition demand. Fortified foods need specialty ingredients. Respiratory care. Chronic conditions bring repeat prescriptions. Specialty chemistry. Fluorochemicals serve many end uses. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Sudeep Pharma performed financially?
Ans. Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%. In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P/E of 61.8, above the industry P/E of 35.1. Looking ahead, excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.
How has Cipla performed financially?
Ans. Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0. Looking ahead, the company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.
How has SRF performed financially?
Ans. Revenue rose from Rs 12,549 crore in FY22 to Rs 15,894 crore in FY26, a compound annual growth rate of 6.1%. Net profit grew from Rs 1,336 crore in FY24 to Rs 1,835 crore in FY26, which works out to a compound annual growth rate of 17.2%. The company has a return on equity of 14.9%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 69,274 crore. The stock trades at a P/E of 30.4, below the industry P/E of 33.9. Looking ahead, the company is expanding in specialty chemicals and refrigerant gases while its packaging films and technical textiles businesses add scale. A mix of segments spreads earnings.
What risks should investors check before buying excipient, respiratory drug and fluorine stocks?
Ans. Investors should check a few risks before buying excipient, respiratory drug and fluorine stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Raw material and energy costs. Input prices can move margins in chemicals. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of excipient, respiratory drug and fluorine stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 29 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
